PARP1 and prostate carcinoma: A number of preclinical studies in a variety of cancer types, such as breast, ovarian and prostate cancer, have shown that PARP inhibition can enhance the effects of various chemotherapies and IR [12–15, 18, 20, 23, 24, 25].